Cargando…

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”

This editorial reflects on improvements in the cancer drug approval process of the U.S. Food and Drug Administration.

Detalles Bibliográficos
Autor principal:	Chabner, Bruce A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507657/ https://www.ncbi.nlm.nih.gov/pubmed/28576859 http://dx.doi.org/10.1634/theoncologist.2017-0202

Ejemplares similares

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

New Results Will Change the Paradigm for Phase I Trials and Drug Approval
por: Chabner, Bruce A.
Publicado: (2010)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Supreme Court and the Practice of Oncology
por: Chabner, Bruce A, et al.
Publicado: (2022)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Academia–Pharma Intersect: Providing a Broader Perspective on Drug Development Synergies between Academia and Industry
por: Chabner, Bruce A.
Publicado: (2010)

Endpoint surrogacy in oncology Phase 3 randomised controlled trials
por: Zhang, Jianrong, et al.
Publicado: (2020)

Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation
por: Herink, Megan C., et al.
Publicado: (2022)

While We’re at It, Let’s Whack the FDA
por: Chabner, Bruce A.
Publicado: (2016)

Reflections on 2015
por: Chabner, Bruce A.
Publicado: (2016)

Understanding the Precision in “Precision Medicine”
por: Chabner, Bruce A.
Publicado: (2016)

Does Chemotherapy Induce Metastases?
por: Chabner, Bruce A.
Publicado: (2018)

Taking the Longer View of COVID‐19
por: Chabner, Bruce A.
Publicado: (2020)

Stepping Down, Looking Forward
por: Chabner, Bruce A
Publicado: (2022)

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions
por: Cavagna, Lorenzo, et al.
Publicado: (2014)

FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
por: Sheikh, Ayesha, et al.
Publicado: (2022)

Biobanking in the era of precision oncology
por: Saini, Kamal S., et al.
Publicado: (2015)

Biomarkers in the Era of Precision Oncology
por: Baxevanis, Constantin N.
Publicado: (2023)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Novel strategies for immuno-oncology breakthroughs with cell therapy
por: Liu, Hongtao, et al.
Publicado: (2021)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
por: Singh, Manish, et al.
Publicado: (2011)

Will the hydrogen therapy be approved shortly?
por: Ohta, Shigeo
Publicado: (2020)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration–approved solid tumor therapies, 1995-2021
por: Alabaku, Orges, et al.
Publicado: (2022)

Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
por: Nicola, Stefania, et al.
Publicado: (2019)

Let This Be Our New Year's Pledge
por: Chabner, Bruce A., et al.
Publicado: (2017)

Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research
por: Chabner, Bruce A., et al.
Publicado: (2018)

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
por: Kakkis, Emil D, et al.
Publicado: (2015)

Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008–2012)
por: Bansal, Dipika, et al.
Publicado: (2015)

Radiation oncology in the new virtual and digital era
por: Aznar, Marianne C., et al.
Publicado: (2021)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
por: Vivot, Alexandre, et al.
Publicado: (2017)

Individualized prognostic calculators in the precision oncology era
por: Taylor, Jeremy M.G., et al.
Publicado: (2019)

Dawn of a new era of diabeto‐oncology
por: Noto, Hiroshi
Publicado: (2020)

Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
Publicado: (2019)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nup3um0545hs5snhoh8q09q7q4